Fresenius Medical Care AG & Co. KGaA

  • WKN: 578580
  • ISIN: DE0005785802
  • Land: Deutschland

Nachricht vom 14.06.2019 | 14:12

Fresenius Medical Care AG & Co. KGaA: Release of a capital market information

Fresenius Medical Care AG & Co. KGaA / Notification pursuant to Article
5(1)(a) of Regulation (EU) No 596/2014 and Article 2(1) of Delegated
Regulation (EU) No 2016/1052

14.06.2019 / 14:12
Dissemination of a Post-admission Duties announcement transmitted by DGAP -
a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Fresenius Medical Care AG & Co. KGaA ('Fresenius Medical Care' or the 'Company') will implement a share buy-back programme. The Company will make use of the authorization granted by the General Meeting on 12 May 2016 to acquire own shares pursuant to section 71 para. 1 no. 8 of the German Stock Corporation Act (Aktiengesetz - AktG). Under this share buy-back programme, up to a maximum of 12 million ordinary shares (ISIN DE0005785802) will be repurchased at a total purchase price (excluding ancillary transaction costs) of up to 660 million Euro (approximately 745 million U.S. Dollar) in the period from 17 June 2019 until and including 17 June 2020. This corresponds to approximately 3.2% of the share capital of Fresenius Medical Care. The own shares repurchased by the Company will be used for the sole purpose of reducing the registered share capital by cancellation of the repurchased own shares. The shares will be repurchased on the stock exchange via the XETRA trading system and/or via selected multilateral trading facilities (MTF). Pursuant to the conditions of the repurchase authorization granted by the Company's General Meeting on 12 May 2016, the price per share (excluding ancillary transaction costs) paid by the Company must not exceed or fall short of the market price of the Company's shares determined by the opening auction on the exchange trading day in the XETRA trading system by more than 10%. The share buy-back will be made in accordance with the safe harbour provisions pursuant to Article 5 of Regulation No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) in conjunction with the provisions of the Commission Delegated Regulation 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to share buy-back programmes and stabilisation measures ('Delegated Regulation'). The share buy-back programme will be led by a credit institution on behalf and for the account of the Company, and such credit institution will make its decisions on the time of the buy-back of shares of Fresenius Medical Care independent of and without being influenced by the Company. In particular, the credit institution has agreed vis-à-vis Fresenius Medical Care to comply with the conditions of the repurchase authorization granted by the Company's General Meeting on 12 May 2016 and the conditions for trading pursuant to Article 3 para. 2 and para. 3 of the Delegated Regulation when executing the share buy-back programme. Pursuant to Article 3 para. 2 of the Delegated Regulation, shares may not be purchased under the share buy-back programme at a price higher than the higher of the price of the last independent trade and the highest current independent purchase bid on the trading venue where the purchase is carried out; at the same time, pursuant to Article 3 para. 3 of the Delegated Regulation, under the share buy-back programme, not more than 25% of the average daily volume of the shares on the trading venue on which the purchase is carried out may be purchased, whereby the average daily volume will be based on the average daily volume traded on the 20 trading days preceding the date of purchase. The share buy-back programme may, to the extent necessary and permitted by law, be suspended and also be reinstated at any time. Fresenius Medical Care will appropriately make available in detailed and aggregated form any information on any transactions in connection with the share buy-back programme no later than at the end of the seventh trading day after executing such transactions. In addition, Fresenius Medical Care will publish the notified transactions on its website at www.freseniusmedicalcare.com under section Investors and ensure that such information will be publicly accessible for at least five year from the day of the announcement. Fresenius Medical Care AG & Co. KGaA represented by Fresenius Medical Care Management AG represented by its Management Board Bad Homburg v.d.H., 14 June 2019
14.06.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language: English Company: Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany Internet: www.freseniusmedicalcare.com End of News DGAP News Service

Anleihe im Fokus

Ekosem-Agrar AG: 7,50%-Anleihe kann ab heute gezeichnet werden.

Emissionsvolumen der 5-jährigen Anleihe bis zu 100 Mio. Euro, Zeichnungsfrist vom 28.06.- 26.07.2019 (voraussichtlich)


- WKN/ ISIN: A2YNR0 / DE000A2YNR0
- Stückelung: 1.000 Euro
- Kupon: 7,50 Prozent p.a.
- Laufzeit: 5 Jahre
- Rückzahlung: 1. August 2024 (Call Option ab 1. August 2021)
- Zinszahlung: Jährlich, jeweils am 1. August

Anleihe im Fokus

6%-MOREH-Anleihe: JETZT ZEICHNEN, Börse München

Immobilienbestandshalter bietet diversifiziertes Portfolio, attraktiven Kupon und umfangreiche Sicherheiten


- Emissionsvolumen bis zu 35 Mio. Euro
- ISIN DE000A2YNRD5
- Kupon 6%, Laufzeit 5 Jahre, halbjährliche Zinszahlung
- Familiengeführte Immobilien Gruppe mit jahrzehntelangem Track Record.
- Diversifiziertes Objekt-Portfolio im Wert von ca. 77 Mio. Euro
- Familiengeführte Immobilien Gruppe mit jahrzehntelangem Track Record.
- Umfangreiche Besicherung u.a. 100%ige Ausschüttungssperre, Verpfändung der Immobiliengesellschaften

Interview im Fokus

„Schnelleres Wachstum mit Wasserstoff“

Mit dem Einstieg in die Wasserstoff-Technologie erschließt sich SFC Energy ein besonders dynamisches Segment. „Mittelfristig ist das Marktvolumen für Wasserstoff-Brennstoffzellen noch größer als im Direkt-Methanol-Bereich. Zivile Massenanwendungen könnten sich dabei zu einem echten Wachstumsbooster entwickeln“, ist CEO Dr. Peter Podesser überzeugt. Im Financial.de-Interview spricht der SFC-Vorstandschef u. a. über die aktuelle Euphorie für Brennstoffzellen-Aktien, die geplante Kapitalmaßnahme und das mittelfristige Umsatzziel von 100 Mio. Euro.

GBC-Fokusbox

Studie GBC Best of m:access I.2019: Weiter im Aufwind und mit starker Outperformance

Das Qualitätssegment m:access hat sich in den letzten Jahren fulminant entwickelt und ist auch 2018 weiter gewachsen. Zuletzt umfasste der m:access einen Rekordwert von 60 Unternehmen unterschiedlichster Branchen mit einer Gesamtmarktkapitalisierung von rund EUR 12 Mrd. Der von GBC berechnete m:access Index hat im Betrachtungszeitraum eine starke Outperformance gezeigt. Auch für die neue Top 15 Best-Of-Auswahl sind die Analysten wieder sehr positiv gestimmt. Die Studie steht kostenlos zum Download zur Verfügung.

News im Fokus

Wirecard und ALDI unterzeichnen MOU und vereinbaren Zusammenarbeit

19. Juli 2019, 07:00

Aktueller Webcast

Westwing Group AG

Webcast H1 2019 Earnings Call

13. August 2019

Aktuelle Research-Studie

ad pepper media International N.V.

Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Hinzufügen

19. Juli 2019